SK Biopharmaceuticals found joint venture with Glycyx

Published: 2018-01-10 16:26:00
Updated: 2018-01-10 16:18:51

SK Biopharmaceuticals(CEO Jung-Woo Cho) announced the company founded a joint venture to develop Relenopride as a rare nervous disease treatment with Glycyx Therapeutics Ltd. On the 7th. SK Biopharmaceuticals and Glycyx will start its clinical development from the year of 2018 after founding the ...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.